4324-37-2

Usage

Uses

Used in Pharmaceutical Industry:
2-methoxypropionic acid is used as a solvent for the production of pharmaceuticals. Its ability to dissolve a wide range of substances makes it an ideal choice for this application.
Used in Electronics Industry:
In the electronics industry, 2-methoxypropionic acid serves as a solvent for various processes, including the manufacturing of electronic components and devices. Its properties allow for efficient and effective dissolution of materials used in this sector.
Used in Coatings Industry:
2-methoxypropionic acid is utilized as a solvent in the production of coatings, such as paints and varnishes. Its solubility properties contribute to the creation of high-quality and durable coatings.
Used in Fragrance Production:
2-methoxypropionic acid is used as a raw material for the production of esters, which are commonly used as fragrances. These esters provide pleasant and distinctive scents for various applications.
Used in Flavoring Industry:
This chemical compound is also used in the production of esters for flavorings, enhancing the taste and aroma of food products and beverages.
Used in Plasticizer Production:
2-methoxypropionic acid is utilized in the synthesis of plasticizers, which are additives that increase the flexibility and workability of plastics. These plasticizers are essential in the manufacturing of various plastic products.
Used in Organic Synthesis:
2-methoxypropionic acid has been studied for its potential use in organic synthesis, where it can serve as a building block for the creation of more complex organic compounds.
Overall, 2-methoxypropionic acid is a versatile chemical with numerous industrial applications, including its use as a solvent, raw material for ester production, and in organic synthesis. Its unique properties make it valuable across various industries, such as pharmaceuticals, electronics, coatings, fragrances, flavorings, and plasticizer production.

InChI:InChI=1/C4H8O3/c1-3(7-2)4(5)6/h3H,1-2H3,(H,5,6)

Upstream product

• 17639-76-8 methyl 2-methoxypropionate 
• 849585-22-4 LACTIC ACID 
• 77-78-1 dimethyl sulfate 
• 124-41-4 sodium methylate 
• 535-11-5 Ethyl 2-bromopropionate 
• 25774-52-1 2-methoxy-propionic acid-anhydride 
• 26728-55-2 2-[(E)-Hydroxyimino]-3-methoxy-butyronitrile 
• 598-72-1 2-Bromopropionic acid 
• 4324-39-4 ethyl 2-methoxypropionate 
• 74-88-4 methyl iodide 
• 41918-08-5 ethyl (S)-2-methoxypropanoate 
• 67-56-1 methanol 
• 27871-49-4 (S)-Methyl lactate 
• 547-64-8 methyl lactate 

Downstream Products

• 4324-39-4 ethyl 2-methoxypropionate 
• 60359-75-3 2-Methoxy-propionic acid 2-phenoxy-ethyl ester 
• 23953-00-6 (S)-2-methoxypropanoic acid 
• 17639-76-8 methyl 2-methoxypropionate 
• 10224-93-8 1,1-bis-(2,5-dimethyl-phenyl)-ethane 
• 67-56-1 methanol 
• 201230-82-2 carbon monoxide 
• 75-07-0 acetaldehyde 
• 1742-14-9 1,1-bis(3,4-dimethylphenyl)ethane 
• 10224-95-0 1,1-bis-(2,4-dimethyl-phenyl)-ethane 
• 530-45-0 1,1-di(4-methylphenyl)ethane 
• 217806-32-1 N-[1-(Dimethyl-phenyl-silanyl)-propyl]-2-methoxy-propionamide 
• 217806-31-0 N-[1-(Dimethyl-phenyl-silanyl)-octyl]-2-methoxy-propionamide 
• 10543-21-2 1,1-bis(4-methoxyphenyl)ethane 

Relevant academic research and scientific papers

Access to Optically Enriched α-Aryloxycarboxylic Esters via Carbene-Catalyzed Dynamic Kinetic Resolution and Transesterification

Optically active α-aryloxycarboxylic acids and their derivatives are important functional molecules. Disclosed here is a carbene-catalyzed dynamic kinetic resolution and transesterification reaction for access to this class of molecules with up to 99% yields and 99:1 er values. Addition of a chiral carbene catalyst to the ester substrate leads to two diastereomeric azolium ester intermediates that can quickly epimerize to each other and thus allows for effective dynamic kinetic resolution to be realized. The optically enriched ester products from our reaction can be quickly transformed to chiral herbicides and other bioactive molecules.

Stereodivergence in the Ireland-Claisen Rearrangement of α-Alkoxy Esters

A systematic investigation into the Ireland-Claisen rearrangement of α-alkoxy esters is reported. In all cases, the use of KN(SiMe3)2 in toluene gave rearrangement products corresponding to a Z-enolate intermediate with excellent diastereoselectivity, presumably because of chelation control. On the other hand, chelation-controlled enolate formation could be overcome for most substrates through the use of lithium diisopropylamide (LDA) in tetrahydrofuran (THF).

NEAR-INFRARED-RAY-ABSORBING COMPOSITION, NEAR-INFRARED-RAY CUT FILTER USING SAME, MANUFACTURING METHOD THEREFOR, CAMERA MODULE, AND MANUFACTURING METHOD THEREFOR

Provided are a near-infrared-ray-absorbing composition having strong near-infrared shielding properties when a cured film is produced, a near-infrared-ray cut filter, a manufacturing method therefor, a camera module, and a manufacturing method therefor. The near-infrared-ray-absorbing composition includes a copper complex obtained by reacting a compound (A) having at least two coordination sites with a copper component.

Developing Pd(II) catalyzed double sp3 C-H alkoxylation for synthesis of symmetric and unsymmetric acetals

An effective Pd(II) catalyzed double unactivated C(sp3)-H alkoxylation has been developed to prepare both symmetric and unsymmetric acetals. This new reaction demonstrates good functional group tolerance, excellent reactivity, and high yields. A variety of novel acetals can be readily accessed via this new method. (Chemical Equation Presented).

PREPARATION OF ALPHA, BETA-UNSATURATED CARBOXYLIC ACIDS AND ESTERS THEREOF

An L-type zeolite, a modified L-type zeolite, or any combination thereof may be useful in catalytically preparing α,β-unsaturated carboxylic acids and/or esters thereof through reaction pathways that include dehydroxylation reactions and optionally esterification reactions. In some reaction pathways, dehydroxylation reactions and esterification reactions may be performed sequentially or concurrently.

METABOTROPIC GLUTAMATE RECEPTORS 5 MODULATORS AND METHODS OF USE THEREOF

Compounds that modulate GluR5 activity and methods of using the same are disclosed.

TRICYCLIC PYRIDINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION

Compounds of formula (I) wherein the groups R1 to R8 have the meanings indicated in the description, the tautomers.the stereoisomers.the mixtures thereof and the salts thereof have valuable pharmacological properties.which make them useful for the treatment of cardiovascular and related disorders.

1,3-THIAZOLE-5-CARBOXAMIDES USEFUL AS CANCER CHEMOTHERAPEUTIC AGENTS

This invention relates to novel 1, 3- thiazole-5 -carboxamide compounds of formula (I), pharmaceutical compositions containing such compounds, and the use of those compounds or compositions as cancer chemotherapeutic agents.

1-METHYL-1H-PYRAZOLE-4-CARBOXAMIDES USEFUL AS CANCER CHEMOTHERAPEUTIC AGENTS

This invention relates to novel 1 -Methyl- lH-pyrazole-4-carboxamide compounds, pharmaceutical compositions containing such compounds, and the use of those compounds or compositions as cancer chemotherapeutic agents.

2-AMINOARYLCARBOXAMIDES USEFUL AS CANCER CHEMOTHERAPEUTIC AGENTS

A compound having the formula (1) in which the ring containing E is a phenyl, a pyridine, or a pyrimidine. In formula (1) the symbol A represents (see structures) wherein the group R4 represents halogen, CF3, or H, provided that the maximum number of CF3 groups on any A is 2, and the maximum number of hydrogens on A is 2 for the A groups which together with the carbon atoms to which they are attached form 6-membered rings, and the maximum number of hydrogens on A is 1 for the A group which together with the carbon atoms to which it is attached forms a 5-membered ring. Z represents N or CH when E forms a phenyl ring, and represents CH when E forms a pyridine or pyrimidine. The groups R1, R2 and R3 and the subscripts a, b, and d are as defined in the text and claims. Pharmaceutical compositions containing a compound of formula (1) and methods of treating cancer using compounds of formula (1) are also disclosed and claimed.